Home > Healthcare > Medical Devices > Diagnostic Devices > D-dimer Testing Market

D-dimer Testing Market Size

Report ID: GMI5972
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

D-dimer Testing Market Size

D-Dimer Testing Market size was valued at over USD 1 billion in 2022 and is projected to reach more than USD 2 billion by 2032. D-dimer testing is a laboratory test used to detect the presence of D-dimer in the blood. D-dimer is a small protein fragment that is produced when a blood clot is dissolved in the body. It is considered a fibrin degradation product.

To get key market trends

Download Free Sample

Additionally, the growing prevalence of blood clotting related genetic disorders is accelerating market growth. Genetic disorders that increase the risk of blood clot formation are uncommon but can have serious health implications. For instance, protein C and protein S deficiencies are rare, with estimated frequencies of around 1 in 300 to 500 individuals for protein C deficiency and 1 in 20,000 to 25,000 individuals for protein S deficiency.

D-dimer Testing Market Report Attributes
Report Attribute	Details
Base Year:	2022
D-dimer Testing Market Size in 2022:	USD 1.2 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	4.3%
2032 Value Projection:	USD 1.9 Billion
Historical Data for:	2018 to 2022
No. of Pages:	200
Tables, Charts & Figures:	279
Segments covered:	Testing Method, Application, End-use, and Region
Growth Drivers:	Growing prevalence of blood clotting related genetic disorders Technological advancements regarding D-dimer testing Increasing demand for next-generation point-of-care (POC) D-dimer tests Government initiatives towards generating awareness regarding blood clotting disorders
Pitfalls & Challenges:	Lack of trained healthcare professionals Stringent reimbursement scenario

Learn more about the key segments shaping this market

Download Free Sample

Moreover, increasing demand for next-generation point-of-care (POC) D-dimer tests. POC D-dimer tests enable healthcare providers to immediately rule out or confirm the presence of a thrombotic event, guiding further diagnostic evaluations or treatment plans. Rapid decision-making can lead to more efficient patient management, potentially reducing unnecessary imaging procedures, hospital admissions, and associated costs, thereby augmenting market expansion.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The global market for d-dimer testing was over USD 1 billion in 2022 and will reach more than USD 2 billion by 2032.

The enzyme-linked immunosorbent assay (ELISA) segment will record more than USD 700 million by 2032 as they are highly sensitive and capable of detecting even low levels of D-dimer in blood samples.

The U.S. d-dimer testing industry accounted for more than USD 450 billion in 2022 and will grow to USD 615 billion by 2032 owing to the affordability of d-dimer testing among the target population base and ongoing technological developments.

Abbott Laboratories, BioMedica Diagnostics, biomérieux SA, Diazyme Laboratories Inc. (General Atomics), F. Hoffmann-La Roche Ltd., HORIBA Ltd., Quidel Corporation, Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.), Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.